Concept↦Quality and Risk↦Study Feasibility↦Aim
What is it? Why is it important?
The aim of study feasibility is to evaluate, based on a set of criteria, the likelihood that a study can be implemented.
Questions to ask include:
- Are study aim and research question(s) clear and well defined?
- Is the target population well defined and available?
- Does the study provide valuable information (e.g. to target population, the therapeutic area)?
- What would be the scope of a fit for purpose study design?
- Are selected sites able to conduct the study (e.g. resources, expertise, infrastructure)?
- Based on study risk-category (A, B or C) what are the organisational implications, such as:
- Safety documentation and assessment
- Submission requirements (e.g. Ethics Committee (EC), Swissmedic, FOPH)?
- What is the expected budget and what are the financial means?
Already at study planning the SP-INV should implement a “Quality-by-Design” (QbyD) approach. This ensures that the study will be fit for purpose providing credible and valuable research results.
More
When planning a study, many potential risks must be taken into consideration. In the Swiss law risks are defined based on type of study and its intervention:
- Studies under ClinO
- Medicinal products: Risk category A, B and C with category C having the highest risk
- Other clinical trials: Risk category A and B, with category B having the highest risk
- Studies under ClinO-MD
- Medical Device: Risk category A and C, with category C having the highest risk
- Decisions regarding target population
- Adults, children, adolescents
- Participants with or without capacity
- Participants in an emergency situation
- Type of intervention
- With or without expected direct benefit
- With or without minimal risks and burdens
Depending on risk category, the required risk management approaches and the extent of the risk based QMS should be adapted proportionally.
What do I need to do?
As a SP-INV, assess study feasibility from a SP-INV perspective, such as:
- Potential scientific significance of the study
- Available expertise (e.g. project-, data-manager, monitors, statistician)
- Available partners (e.g. study site(s), service providers such as laboratories)
- Study set-up and management based on a Quality by Design (QbyD) approach
- Management of study risks focusing on Critical to Quality (CtoQ) factors (e.g. participant right and safety, data quality)
- Study design feasibility (e.g. blinded, randomized)
- Access to funds
As a SP-INV together with the Site-INV, assess study feasibility from a study-site perspective, such as:
- Available infrastructure (e.g. access protected storage facilities, workspace, patient rooms, laboratory facilities, handling of biological material (e.g. sample workflow), facilities and material such as freezers)
- Available expertise (e.g. expert physician(s), study nurse, site coordinator)
- Access to target population (e.g. sufficient number of patients willing to participate)
- Adequate time at disposal to conduct the study
Where can I get help?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
References
ICH GCP E6(R3) – see in particular guideline
- 2.3 Responsibilities
- 3.10 Quality management
ICH E8(R1) – see in particular
- 3.1 Quality by Design of clinical studies
- 3.2 Critical to Quality Factors
ISO 14155 (access liable to costs) – see in particular section
- Medical Device
Swiss Law
HRA – see in particular articles
- Art.16/24 Adults
- 22 Children
- 30/31 Emergency
ClinO – see in particular articles
- Art. 19–23a Approval and Notification Procedures for Clinical Trials of Medicinal Products, Products under Article 2a paragraph 2 TPA and Transplant Products
- Art. 61 Risk categorisation
ClinO-MD - see in particular article
- Art. 6 Categorization of clinical investigations